CLAIMS

1. A capsule for oral administration comprising a pharmaceutical composition comprising:

    (i) alisporivir in an amount of about 15% to about 20% by weight of the composition,
    (ii) water in an amount of about 2% to about 15% by weight of the composition,
    (iii) a lipophilic component,
    (iv) a surfactant; and
    (v) a hydrophilic component comprising ethanol.

2. The capsule for oral administration according to claim 1, wherein the pharmaceutical composition comprises water in an amount of about 4% to about 15% by weight of the composition.

3. The capsule for oral administration according to claim 1, wherein the pharmaceutical composition comprises water is in an amount of about 3% to about 10% by weight of the composition.

4. The capsule for oral administration according to any one of claims 1 to 3, wherein the pharmaceutical composition comprises water in an amount of about 4% to about 5% by weight of the composition.

5. The capsule for oral administration according to any one of claims 1 to 4, wherein the pharmaceutical composition comprises alisporivir in an amount of about 19% to about 20% by weight of the composition.

6. The capsule for oral administration according to any one of claims 2 to 5, wherein the pharmaceutical composition comprises a hydrophilic component which further comprises one of the compounds selected from the group consisting of polyethyleneglycol, triethylcitrate, diethylene glycol monoethyl ether and propylene glycol, preferably selected from the group consisting of polyethyleneglycol and propylene glycol.

7. The capsule for oral administration according to any one of claims 2 to 6, wherein the pharmaceutical composition comprises a lipophilic component selected from the group consisting of medium chain triglycerides, corn oil mono- di- triglycerides, sorbitan monooleate, linoleoyl macrogolglycerides and oleic acid, preferably selected from the group consisting of medium chain triglycerides and sorbitan monooleate.

8. The capsule for oral administration according to any one of claims 2 to 7, wherein the pharmaceutical composition comprises a surfactant selected from the group consisting of Macrogolglycerol hydroxystearate, Caprylocaproyl Macrogol-8 glycerides, Vitamin E Polyethylene Glycol Succinate and Glyceryl caprylate, preferably selected from the group consisting of Macrogolglycerol hydroxystearate, Caprylocaproyl Macrogol-8 glycerides and Vitamin E Polyethylene Glycol Succinate.

9. The capsule for oral administration according to any one of claims 1 to 8, wherein the pharmaceutical composition contains from about 50 to about 400 mg alisporivir, preferably about 100 or about 200 mg alisporivir.

10. The capsule for oral administration according to any one of claims 1 to 9 wherein the capsule is a soft gelatin capsule, a hard gelatin capsule or a HPMC-based capsule or a Vegicap.